| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
BerGenBio ASA (OL: BGBIO)
BGBIO Technical Analysis
5
| As on 9th Jun 2023 BGBIO STOCK Price closed @ 0.32 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 14.05 & Strong Sell for SHORT-TERM with Stoploss of 18.83 we also expect STOCK to react on Following IMPORTANT LEVELS. |
BGBIOSTOCK Price
| Open | 0.33 | Change | Price | % |
| High | 0.34 | 1 Day | 0.00 | 0.00 |
| Low | 0.30 | 1 Week | 0.02 | 6.67 |
| Close | 0.32 | 1 Month | -4.38 | -93.19 |
| Volume | 2550157 | 1 Year | -18.56 | -98.31 |
| 52 Week High 21.20 | 52 Week Low 0.26 | ||||
OL Norway Most Active Stocks
| PGS | 6.97 | -3.19% |
| NANOV | 2.23 | -20.64% |
| AOW | 2.00 | -5.21% |
| IDEX | 0.71 | 0.00% |
| ENSU | 0.12 | 0.00% |
| SCANA | 1.99 | 2.05% |
| EQNR | 313.65 | 1.98% |
| ACH | 3.90 | 2.36% |
| ARCH | 0.91 | -1.09% |
| NAS | 12.12 | 0.83% |
OL Norway Top Gainers Stocks
OL Norway Top Losers Stocks
| BGBIO Daily Charts |
BGBIO Intraday Charts |
Whats New @ Bazaartrend |
BGBIO Free Analysis |
|
|
BGBIO Important Levels Intraday
| RESISTANCE | 0.40 |
| RESISTANCE | 0.37 |
| RESISTANCE | 0.36 |
| RESISTANCE | 0.34 |
| SUPPORT | 0.30 |
| SUPPORT | 0.28 |
| SUPPORT | 0.27 |
| SUPPORT | 0.24 |
BGBIO Forecast April 2024
| 4th UP Forecast | 10.82 |
| 3rd UP Forecast | 7.45 |
| 2nd UP Forecast | 5.37 |
| 1st UP Forecast | 3.29 |
| 1st DOWN Forecast | -2.65 |
| 2nd DOWN Forecast | -4.73 |
| 3rd DOWN Forecast | -6.81 |
| 4th DOWN Forecast | -10.18 |
BGBIO Weekly Forecast
| 4th UP Forecast | 5.91 |
| 3rd UP Forecast | 4.12 |
| 2nd UP Forecast | 3.01 |
| 1st UP Forecast | 1.90 |
| 1st DOWN Forecast | -1.26 |
| 2nd DOWN Forecast | -2.37 |
| 3rd DOWN Forecast | -3.48 |
| 4th DOWN Forecast | -5.27 |
BGBIO Forecast2024
| 4th UP Forecast | 41.27 |
| 3rd UP Forecast | 28.14 |
| 2nd UP Forecast | 20.02 |
| 1st UP Forecast | 11.9 |
| 1st DOWN Forecast | -11.26 |
| 2nd DOWN Forecast | -19.38 |
| 3rd DOWN Forecast | -27.5 |
| 4th DOWN Forecast | -40.63 |
BerGenBio ASA ( OL Norway Symbol : BGBIO )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
BGBIO Business Profile
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the developing drugs to treat immune evasive, drug resistant, and metastatic cancers. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. The company's Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase I clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is headquartered in Bergen, Norway. Address: Jonas Lies vei 91, Bergen, Norway, 5009
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service